EP2588116A4 — FORMULATIONS OF AN INTRAVENOUS SOLUTION OF POSACONAZOLE STABILIZED BY SUBSTITUTED BETA CYCLODEXTRIN
Assigned to Organon Pharma UK Ltd · Expires 2013-12-04 · 12y expired
What this patent protects
The present invention relates to aqueous solutions useful as pharmaceutical compositions of posaconazole for intravenous administration. These compositions include a solubilizing agent, such as a modified beta-cyclodextrin in an acidified solution, which can also include a chelat…
USPTO Abstract
The present invention relates to aqueous solutions useful as pharmaceutical compositions of posaconazole for intravenous administration. These compositions include a solubilizing agent, such as a modified beta-cyclodextrin in an acidified solution, which can also include a chelating agent such as disodium edetate (EDTA). In clinical trials, a 200 mg posaconazole dose of the selected composition was found to achieve acceptable pharmacokinetic properties.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.